In a recent MLex article, Knobbe Martens partner Jeremiah Helm shared his insights on Hikma Pharmaceuticals’ bid for the Supreme Court to grant certiorari in a closely watched “skinny label” case that could have a considerable impact on the generic drug industry.
The article covers the history of Hikma’s dispute with Amarin Pharma regarding generic drug “skinny labels” and the U.S. Solicitor General’s amicus brief urging the Supreme Court to review the Federal Circuit’s 2024 decision that held Amarin’s pleadings set out sufficient allegations to establish a case against Hikma for induced infringement.
Helm suggested that the Solicitor General’s brief underscored the administration’s previously stated focus on generic drug policy, particularly lowering the cost of prescription drugs. He also discussed the potential impact of significant litigation costs on generic drug manufacturers, if the Federal Circuit decision stands.
Read the full article here [subscription required].
Subscribe for News and Updates
